What is Aortic Stenosis and Why Does It Matter in Canada?
Aortic stenosis (AS), also known as calcific aortic valve stenosis, is a progressive heart valve disease where the aortic valve thickens, hardens, and narrows due to calcium buildup. This forces the heart to pump harder, potentially leading to heart failure if untreated. In Canada, AS affects nearly 3% of people aged 65 and older, a demographic expanding rapidly with an aging population. By 2040, projections estimate 1.5 million Canadians over 65 will have some form of heart valve disease, underscoring the urgent need for better strategies.
Symptoms often emerge late—shortness of breath, chest pain, palpitations, dizziness—but early detection is key. Currently, no medications halt progression; options are limited to surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR), both invasive and unsuitable for all patients, especially the frail elderly.
The McGill-Led Genetic Breakthrough in Nature Genetics
A groundbreaking study co-led by McGill University researchers has identified 241 genes linked to AS risk, including 200 previously unknown ones. Published in Nature Genetics in January 2026, the paper "Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction" represents the largest genetic analysis of AS to date.
Dr. George Thanassoulis, senior scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), and Dr. James C. Engert, scientist in the Cardiovascular Health across the Lifespan program, spearheaded this effort alongside Harvard's Pradeep Natarajan and international collaborators. Their work analyzed genetic data from 2.85 million people, including 86,864 AS cases across diverse ancestries.Read the full study
Unpacking the Study's Methodology
The team conducted a multi-ancestry genome-wide association study (GWAS), sex-stratified and ancestry-stratified analyses, plus transcriptome-wide association studies (TWAS) using aortic valve expression quantitative trait loci (eQTLs). This identified 261 independent risk loci (223 novel), with sex-specific and ancestry-specific insights—e.g., 5 male-only loci and additional European/African variants.
TWAS pinpointed 54 new genes where predicted expression affects AS risk. Functional validation involved silencing key genes like CMKLR1 and LTBP4 in human valvular interstitial cells (VICs), reducing mineralization—a hallmark of AS calcification.
Key Genetic Discoveries and Biological Pathways
Among the 241 prioritized genes, disruptions in inflammation (e.g., IL6R, CMKLR1), lipid metabolism (LDLR, PCSK9, LPA), extracellular matrix remodeling, TGFβ signaling (LTBP4), adiposity, and cell cycle arrest emerged. Three genes may explain sex differences in AS prevalence, which is higher in men.
- Lipid pathways: Strong links to LDL-cholesterol, HDL, triglycerides—suggesting statin-like interventions warrant reevaluation.
- Inflammation and calcification: CMKLR1 ties to polyunsaturated fatty acid (PUFA) signaling; silencing blocks calcium buildup.
- TGFβ and cytoskeleton: LTBP4 deactivation halts progression in lab models.
These insights prioritize drug repurposing targets, validated by colocalization with calcific nodules in human valves.MUHC press release
Polygenic Risk Score: Revolutionizing Early Prediction
The study developed a novel polygenic risk score (PRS) using LDpred2, explaining 0.7% of AS variance—doubling prior scores' performance. In validation cohorts (UK Biobank, TIMI, UCLA ATLAS), it yielded hazard ratios up to 1.92 per SD increase, outperforming clinical factors like hypertension except age.
Added to clinical models, PRS boosted C-indexes (e.g., 0.85 to 0.87) and net reclassification improvement (29%). High-risk individuals (top 20%) face HRs >2 for aortic valve replacement. For Canada, integrating PRS into screening could identify at-risk seniors early, before symptoms.
McGill's Legacy in Cardiovascular Genetics
McGill's RI-MUHC has pioneered AS genetics, with Thanassoulis leading international consortia. Funded by CIHR, Heart & Stroke, FRQS, this builds on prior work linking Lp(a) to AS progression. As Canada's top medical research hub, McGill attracts global talent—ideal for aspiring geneticists eyeing research jobs in cardio-genomics.
Treatment Horizons: From Replacement to Prevention
Today, Canada performs thousands of TAVR/SAVR annually—Ontario alone saw 7,155 TAVR and 14,595 SAVR (2012-2020)—but costs soar ($393M/year for AS hospitalizations). No pharma options exist, but genes like LPA fuel Lp(a)-lowering trials; PCSK9 inhibitors show promise genetically.
PRS-guided trials could test PUFA modulators or TGFβ inhibitors. Dr. Thanassoulis notes: "Our goal is early treatments avoiding valve replacement risks." Dr. Engert adds: "This paves prevention strategies."
Canadian Context: Aging Population and Healthcare Burden
With 22% of Canadians 65+ by 2030, AS cases will surge. CCS calls for national strategies: better screening, TAVR access. Quebec's MUHC exemplifies innovation, but disparities persist—rural/underserved lag. Genetic tools could democratize risk assessment, integrating with Canada's universal care.
Stakeholders praise: Cardiologists seek pharma breakthroughs; patients hope symptom-free lives. Policymakers eye PRS for public health.Career advice for researchers
Challenges and Future Directions
- Validate PRS in diverse Canadians (e.g., Indigenous, South Asian).
- Clinical trials: Lp(a)/lipid-lowering, anti-calcification drugs.
- AI integration for valve imaging + genetics.
- Ethical PRS use: equity in access.
McGill plans functional studies; collaborations expand. Timeline: Preclinical drug tests 2-5 years; trials 5-10.
Careers in Genetic Research: Opportunities at McGill and Beyond
This study spotlights demand for geneticists, bioinformaticians in cardio. McGill's programs train next-gen via PhDs, postdocs. Explore research assistant jobs, postdoc positions, or faculty roles. Rate professors via Rate My Professor; career tips at Higher Ed Career Advice.
Canada's CIHR funds abound—join the revolution transforming heart health.
